Vytala is a company headquartered in the United States.
Vytala develops a plant-based medical food and lipid delivery technology (Lym-X-Sorb) designed to improve absorption of fats, calories, choline, and essential fatty acids for patients with fat malabsorption and gastrointestinal disorders. Clinical studies cited on the company website report improved nutrient absorption and growth metrics in pediatric cystic fibrosis and pancreatic insufficiency patients, and the product is presented as eligible for CMS reimbursement.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.